Jonathan S. Serody MD Curriculum Vitae Departments of Medicine, Microbiology and Immunology Lineberger Comprehensive Cancer Center 450 West Drive Campus Box #7295 University of North Carolina at Chapel Hill Chapel Hill, NC 27599-7295 Phone: 919 966-6975 FAX: 919 966-8212 e-mail: jonathan_serody@med.unc.edu Address of Clinical Investigation: UNC Hospitals The University of North Carolina at Chapel Hill 101 Manning Drive Chapel Hill, NC 27599-7600 Education: Postdoctoral Fellowship Department of Microbiology and Immunology, University of North Carolina at Chapel Hill; mentor Jeffrey Frelinger PhD, 1990-1993 Fellowship in Clinical Bone Marrow Transplantation: Fred Hutchinson Cancer Research Center, 1993 Fellowship in Hematology: North Carolina Memorial Hospital, July 1990-Jan 1993 Fellowship Infectious Diseases: North Carolina Memorial Hosp, July 1989-July 1992 Residency in Medicine: North Carolina Memorial Hospital, July 1987-July 1989 Internship in Medicine: North Carolina Memorial Hospital, July 1986-July 1987 Doctor of Medicine University of Virginia Med School, July 1982-June 1986 Bachelor of Arts in Biology University of Virginia, July 1978-June 1982 Review Groups, Honors and Awards: 1987: Outstanding Intern University of North Carolina Hospitals 1992: National Research Service Award NIH 1996: KO8 Grant National Cancer Institute 1997: Ad Hoc Member Food and Drug Administration's Fever and Neutropenia Committee 1997-01: Ad Hoc Member National Cancer Institute Scientific Review Group Subcommittee D 1 2000-2002: Ad Hoc Member Parent Committee National Cancer Institute Scientific Review Group Subcommittee D 2001: Member Review Committee SPORE in Gyn Cancer Study Section 2001-2004: Scientific Subcommittee on Transplantation Biology American Society of Hematology 2002: Member Review Committee SPORE in Ovarian Cancer Study Section 2003: Member Review Committee SPORE in Leukemia/Lymphoma 2003: Presentation on Update in GVHD Biology American Society of Hematology Meeting 2003: Ad hoc Member Immunotherapy-Gene Therapy P01 Cluster Review NCI 2004-2007: Member SPORE Parent Committee 2005, 2006: Ad hoc Member CONC Study Section 2005: Ad hoc Member TTT Study Section 2005: Grant Review Wellcome Trust UK 2005-2012: Standing member Leukemia and Lymphoma Society TRP Grant Review 2005-present: co-leader Immunology Program Lineberger Comprehensive Cancer Center 2006: Named Elizabeth Thomas Associate Professor of Medicine, Microbiology and Immunology 2005-2012: Castle Connolly America’s Top Doctors in Cancer 2006-2012 Castle Connolly America’s Top Doctors 2006-2012: Member LRP Study Section 2007-2010: Standing Member TTT Study Section 2007-2009: Interim leader Malignant Hematology Program Lineberger Comprehensive Cancer Center 2008-present: External Advisory Board Johns Hopkins School of Medicine Breast Cancer Program 2008-2013: Scientific Subcommittee Lymphocyte Biology and Host Defense American Society of Hematology 2008-present: Hematology and Oncology Division Research Coordinator 2009-2012: CIBMTR Scientific Committee on Immunosurveillance 2010-present: Leader Malignant Hematology Program Lineberger Comprehensive Cancer Center 2010-2012: External Advisory Board Duke University Medical School Lymphoma Program 2010-present: Section Chief: Leukemia, Lymphoma and Myeloma Program Division of Medical Oncology 2010: CCSG Review Group University of Maryland Cancer Center 2011: Presidential Symposium Address American Association for Immunology 2011: ASH Basic Science Scholar Grant Review Group 2012: Chair SEP for RFA Review for NHLBI RFA “Early Phase Clinical Trials for Blood Therapies.” 2012: Invited Talk ASBMT meeting “Th17/Th22 Cells Key Actors or Bit Players in Acute GvHD.” 2012: Reviewer for NHLBI SEP ZRG1-OTC-C: SEP for TTT Members 2012: ASH Basic Science Scholar Grant Review Group Employment History: December 2010-present Leader Malignant Hematology Program Lineberger Cancer Center August 2010-present Section Chief Leukemia, Lymphoma and Myeloma Service Division of Medical Oncology the University of North Carolina at 2 July 2008-present November 2006 July 2000 July 1998 July 1993 – July 2000: Chapel Hill, NC Elizabeth Thomas Professor of Medicine, Microbiology and Immunology, The University of North Carolina at Chapel Hill, NC. Elizabeth Thomas Endowed Associate Professor of Medicine, Microbiology and Immunology Associate Professor of Medicine, The University of North Carolina at Chapel Hill, NC Joint Appointment in Microbiology and Immunology The University of North Carolina at Chapel Hill Assistant Professor of Medicine, The University of North Carolina at Chapel Hill, NC Bibliography Peer Reviewed 1. Lin K, Coghill JM, West ML, Dustin M, Bear JM, Serody JS. Intravital imaging reveals multiple mechanisms for regulatory T cell function during GVHD. Nature Medicine (under review). 2. Dharmasiri U, Vincent, BV, , Hunsucker SA, Alatrash G, Sarantopoulos S, Serody JS, Molldrem JJ, Armistead PM. Use of RNA sequencing to identify antigens from RNA spliced variants from leukemia stem cell blasts. Science Translational Medicine (under review). 3. Fulton LM, West ML, Coghill JM, Panoskaltsis-Mortari A, Bear JM, Foger N, Serody JS. Absence of Coronin 1A markedly attenuates GVHD by preventing lymphocyte migration and egress from secondary lymphoid tissue. Blood (under review). 4. Coghill JM, Fowler K, West ML, Bear J, Panoskaltsis-Mortari A, Power C, Serody JS. APC interaction via CCR8 is required for the longitudinal persistence of regulatory T cells after stem cell transplantation. Blood (under revision). 5. Wu QP, Serody JS, Van Deventer HW. Fibrocytes are critical to the recruitment of CD11b+ myeloid cells and the promotion of lung metastases. PLoS Biology (under review) 6. Mango RL, Wu QP, West ML, Davis BK, Serody JS, van Deventer HW. CC-Chemokine Receptor 5 on Pulmonary Mesenchymal Cells Promotes Metastasis through Induction of Erythroid Differentiation Regulator 1. Clinical and Experimental Metastasis (submitted). 7. Allen, JL, Fore MS, Wooten J, Roerhs PA, Nazmim BS, Hoffert T, Sharf A, Deal A, Armistead PM, Coghill JM, Gabriel D, Irons RN, Essenmacher A, Shea TC, Richards KL, Cutler C, Ritz J, Serody JS, Baldwin AS Jr. B cells from patients with chronic 3 GVHD are activated and primed for survival via BAFF mediated pathways. Blood. 2012 Aug 14 [Epub ahead of print] 8. Fedoriw Y, Samulski TD, Deal AM, Dunphy CH, Sharf A, Shea TC, Serody JS. Sarantopoulos S. Bone marrow B cell precursor number after allogeneic stem cell transplantation and GVHD development. Biology of Blood and Marrow Transplantation. 18(6): 968-973, 2012. 9. Fulton, LM, Carlson MJ, Coghill JM, Ott LE, West ML, Panoskaltsis-Mortari A, Littman DR, Blazar BR, Serody JS. Critical role for RORt expression by CD4+ T cells in GvHD mediated by CD8+ T cells. The Journal Immunology 189(4) 1765-1772, 2012. 10. Wood, W, Deal A, Whitley J, Sharf A, Serody J, Gabriel D, Shea T. Usefulness of the hematopoietic cell transplantation-specific comorbidity index (HCT-IC) in predicting outcomes for adolescents and young adults with hematologic malignancies undergoing allogeneic stem cell transplant. Pediatric Blood Cancer 2011 Mar 7 doi 10, 1002/pbc23057 epub ahead of print. 11. Beaven AW, Moore DT, Sharf A, Serody JS, Shea TC, Gabriel DA. Infusional mitoxantrone plus bolus melphalan as a stem cell transplant conditioning regimen for multiple myeloma. Cancer Investigations. 29(3): 214-219, 2011. 12. Coghill, JM, Sarantopoulos S, Moran TP, Murphy WJ, Blazar BR, Serody JS. Effector CD4+ T cells, the cytokines they generate and graft-versus-host disease: Something Old, Something New. Blood . 2011 Jan 18 [Epub ahead of print]. 13. Highfill SL, Rodriguez PC, Zhou Z, Goetz CA, Koehn BH, Veenstra RG, Taylor PA, Panoskaltsis-Mortari A, Serody JS, Munn DH, Tolar J, Ochoa AC, Blazar BR. Bone marrow myeloid-derived suppressor cells (MDSC) inhibit graft-versus-host disease (GVHD) via an arginase-1 dependent mechanism that is upregulated by IL-13. Blood 116(25): 5738-5747, 2010. 14. Carlson M, Fulton, L, Coghill JM, West MJ, Panoskaltsis-Mortari, A, Wan Y, Tedder T, Blazar BR, Serody JS. L-selectin is not absolutely required for regulatory T cell function in GVHD. American Journal of Transplantation, 10(12): 2596-2603, 2010. 15. *Van Deventer H, *Burgents JE, Wu QP, Woodford RM, Brickey WJ, Allen IC, Tekippe EM, **Serody JS, **Ting JPY. The inflammasome component, NLRP3, impairs antitumor vaccination by enhancing accumulation of peritumoral myeloid derived suppressor cells. Cancer Research. 70(24): 10161-10169, 2010.* and ** equally contributed to work 16. Wood WA, Whitley J, Moore D, Sharf A, Iron R, Rao K, Serody J, Gabriel D, Shea T. Chemomobilization with etoposide is highly effective in patients with myeloma and overcomes the effects of age and prior therapy. Biology of Blood and Marrow Transplantation. 17(1): 141-146, 2011. 4 17. Coghill JM, Carlson MJ, Panoskaltsis-Mortari A, West ML, Burgents JE, Blazar BR, Serody JS. Separation of graft-versus-host disease from graft-versus-leukemia responses by targeting C-C chemokine receptor 7 on donor T cells. Blood 115(23): 4914-4922, 2010 (Inside Blood Comment). 18. Burgents, JE, Moran TM, Collier ML, West MJ, Davis NL, Johnston RE, Serody JS. The immunosuppressive tumor environment is the main impediment to successful vaccination in neu transgenic mice. J Immunotherapy 33(5): 482-491, 2010. 19. Wood, W, Garg, S, Adamus G, Gabriel D, Shea T, Serody, J. Alloimmune Retinopathy associated with antibodies to transducin-α as a complication of chronic GVHD. Biol of Blood and Marrow Transplantation DOI: 10:1016/j 06.012, 2009.. 20. Shea TC, Beaven AW, Moore DT, Serody JS, Gabriel DA, Chao NK, Gockerman J, Lindley C, Garcia R, Schell M and Rizzieri DA.Sequential high-dose ifosfamide, carboplastin and etoposide with ritucimab for relapsed Hodgkin and large B-cell nonHodgkin lymphoma: increased toxicity without improvement in progression-free survival. Leukemia & Lymphoma 8(1-8) (epub ahead of print, 2009). 21. Rao, KV, Buie LW, Shea T, Gabriel DA, Comeau T, Irons R, Serody J, Eron B. Intravesicular cidofovir for the management of BK virus-associated cystitis. Biol Blood Marrow Transplant 15(3): 391-392, 2009. 22. O’Shaunessey MJ, Vogtenhuber C, Sun K, Sitcheran R, Baldwin AS, Murphy WJ, Dang L, Jaffee B, Palmer E, Serody JS, Blazar BR..Ex vivo inhibition of NF-kappaB signaling in alloreactive T-cells prevents graft-versus-host disease. American Journal of Transplantation 9(3): 452-462, 2009. 23. Carlson, MJ, West M, Panoskaltsis-Mortari, A, Blazar BR. Serody JS. In vivo generated Th17 cells mediate lethal GVHD with severe cutaneous and pulmonary pathology. Blood113(6): 1365-1374, 2009. 24. Taylor PA, Ehrhardt MJ, Lees CJ, Panoskaltsis-Mortari A, Krieg AM, Sharpe AH, Murphy WJ, Serody JS, Hemmi H, Akira S, Levy RB, Blazar BR. TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection. Blood 112(8): 3508-3516, 2008. 25. Coghill, J, Carlson M, Moran TJ and Serody JS. The biology and therapeutic potential of natural regulatory T-cells in the bone marrow transplant setting. Leukemia and Lymphoma July 25, 1-10, 2008. 26. van Deventer HW, Ping QW, Bergstralh DT, Davis BK, O'Connor BP, Ting JPY and Serody JS. C-C Chemokine Receptor 5 on Pulmonary Fibrocytes Facilitates Migration and Promotes Metastasis via Matrix Metalloproteinase 9. American Journal of Pathology, 173(1): 253-264, 2008. 5 27. Petermann KB, Rozenberg GI, Zedek D, Groben P, McKinnon KP, Buehler C, Kim W, Shields JM, Bear JE, Thomas NE, Serody JS, Sharpless NE. Erk activation induces CD200 expression and T cell suppression in melanoma. Journal of Clinical Investigation 117(12): 3922-3929, 2007. 28. Moran TP, Burgents JE, Long B, Ferrer I, Jaffee EM, Tisch R, Johnston RE, Serody JS. Alphaviral-vector transduced dendritic cells are successful therapeutic vaccines against Neu-expressing tumors. Vaccine 25(36):6604-6612, 2007. 29. Taylor PA, Ehrhardt MJ, Lees CJ, Tolar J, Weigel BJ, Panoskaltsis-Mortari A, Serody JS, Binkmann V, Blazar BR. Insights into the mechanism of FTY720 and compatibility with regulatory T cells for the inhibition of GVHD. Blood 110(9): 3480-3488, 2007 30. Serody J. The CCR deletion mutation and graft-versus-host disease. Haematologica. 91(12): 1586A, 2006 31. Taylor PA Ehrhardt MJ, Roforth MM, Swedin JM, Panoskaltsis-Mortari A, Serody JS, Blazar BR. Preformed antibody, not primed T cells, is the initial and major barrier to bone amrrow engraftment in allosensitized recipients. Blood 109(3): 1307-1315, 2007. 32. Gilman A and Serody JS. Biology and Management of chronic GVHD. Seminars in Hematology 43(1): 70-80, 2006. 33. Gabriel DA, Shea TC, Serody JS, Moore, DT, Kirby SL, Harvey, D, Bigelow SH, and Krasnov C. Cytoprotection by Amifostine (Ethyol®) During Autologous Stem Cell Transplantation for Advanced Refractory Hematologic Malignancies. Biology of Blood and Marrow Transplantation 11(12): 1022-1030, 2005. 34. Taylor, PA, Panoskaltsis-Mortari A, Freeman GJ, Sharpe, AH, Noelle RJ, Rudensky AY, Mak TW, Serody JS, Blazar BR. Targeting of inducible costimulator expressed on alloreactive T cells down regulates graft-versus-host disease and facilitates engraftment of allogeneic bone marrow. Blood. 105(8): 3372-3380, 2005. 35. Moran, T, Collier, M, McKinnon, KP, Davis NL, Johnston RE, Serody JS. A novel viral system for generating antigen-specific T cells. Journal of Immunology. 175(3): 34313438, 2005. 36. Wysocki, C, Panoskaltisis-Mortari, A, Blazar BR, Serody JS. Leukocyte migration and GVHD. Blood. 105(11): 4191-4199, 2005. 37. Wysocki C, McKinnon KM, Raimondo C, Lee H, Su, L, Blazar BR, Serody JS. Critical role for CCR5 in the function of CD4CD25+ regulatory T cells during acute GVHD. Blood 2005 July 7 106(9): 3300-3307, 2005. 6 38. van Deventer H, O’Connor Jr W, Brickey WJ, Aris RM, Ting JPY, Serody JS. Critical role for stromal cell production of CCR5 in pulmonary metastasis. Cancer Research 65: 3374-3379, 2005. 39. Hildebrandt, GC, Olkiewicz, KM, Choi S, Corrion LA, Clouthier S, Liu C, Serody JS, and Cooke KR. Donor T cell production of RANTES significantly contributes to the development of idiopathic pneumonia syndrome after allogeneic stem cell transplantation. Blood. 105:3372-3380, 2005. (Plenary Manuscript) 40. Blazar BR, Levy RB, Mak TW, Mortari-Panoskaltsis A, Muta, H, Jones, M, Roskos, M, Serody JS, Yagita, H, Podack ER, and Taylor PA. CD30/CD30 ligand (CD153) interaction regulates CD4+ T cell mediated graft-versus-host disease. Journal of Immunology. 173:2933-2941, 2004. 41. Taylor, P, Panoskaltsis-Mortari, A, Wilson, J, Lucas, P, Gress, R, Levine, B, June, C, Serody JS, Blazar, BR. L-selectin but not the L-selectin lo CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. Blood 104, 3804-12, 2004. 42. Sun, K, Welniak LA, Panoskaltsis-Mortari, A, O’Shaughnessy, MJ, Liu, H, Barro I, Riordan, W, Sticheran R, Wysocki C, Serody JS, Blazar BR, Sayers, TJ, and Murphy WJ. Inhibition of acute GVHD with promotion of anti-tumor effects by the proteasome inhibitor, bortezemib, after allogeneic bone marrow transplantation. Proceedings of the National Academy of Science USA. 101(21): 8120-8125, 2004. 43. Sauer MG, Ericson ME, Weigel BJ, Herron MJ, Panoskaltsis-Mortari A, Kren BT, Levine BL, Serody JS, June CH, Taylor PA, Blazar BR. A novel system for simultaneous in vivo tracking and biological assessment of leukemia cells and ex vivo generated leukemia-reactive cytotoxic T cells. Cancer Research 64(11): 3914-3921, 2004 44. Wysocki, C, Burkett SE, McKinnon, K Kirby, SL, Luster, A, Blazar BR and Serody JS. Differential role of CCR5 on donor T cells during GVHD based on pretransplant conditioning. Journal of Immunology 173(2)845-854, 2004 45. Dees, EC, McKinnon,van Deventer H, Chwastiak K, Sparks, S, Myers, M, Collins, E, Frelinger J, Collichio, F, Carey, L, Brecher, M, Earp, HS, Graham, M, and Serody JS. Dendritic cells can be rapidly and effectively expanded in patients with metastatic breast cancer. Cancer Immunology Immunotherapy. 53(9): 777-785, 2004. 46. Panoskaltsis-Mortari, A, Price, A, Hermanson, J, Taras, E, Lees, E, Serody JS, Blazar, BR. In vivo imaging of graft-versus-host disease in mice. Blood 103:3590-3598, 2004. 47. Shea, TC, Brunner, R, Wiley, JM, Serody JS, Sailer, S, Gabriel DA, Capel E, Moore, D, Dent, G, Bentley, S and Brecher, M. An Expanded Phase I Trial of Cyclophosphamide, Etoposide, and Carboplatin plus Total Body Irradiation with Autologous Marrow or Stem Cell Support for Patients with Hematologic Malignancies. Biology of Blood and Marrow Transplantation 9(7):443-452, 2003. 7 48. Lindley, C, McCune, JS, Shord, S, Decker, J., Harvey, D., Kirby, SL, Gabriel DA, Petros, WP, Shea TC, Serody JS, and Wiley JM. Intraindividual variability in busulfan pharmacokinetics in patients undergoing a bone marrow transplant: Assessment of a test dose and first dose strategy. Anti-Cancer Drugs. 15(5): 453-459, 2004. 49. Mortari-Panoskaltsis, A, Hermansen, JR, Taras, E, Wangensteen OD, Serody JS, and Blazar BR. Acceleration of idiopathic pneumonia syndrome (IPS) in the absence of donor MIP-1 (CCL3) after allogeneic BMT in mice. Blood. 101: 3714-21, 2003. 50. van Deventer, Serody, JS, McKinnon, KP, Clements, C, Brickey, WJ, Ting JPY. Transfection of Macrophage inflammatory protein 1a into B16-F10 melanoma cells inhibits growth of pulmonary metastases but not subcutaneous tumors. Journal of Immunology 169:1634-1639, 2002. 51. Ng-Cashin, J, Kuhns, JJ, Burkett, S.E., Powderly, JD, Craven, RR, van Deventer, HW, Kirby, SL and Serody JS. Host absence of CCR5 potentiates DC vaccination. Journal of Immunology. 170: 4201-08, 2003. 52. Serody JS, Burkett S, Mortari-Panoskaltsis A., Ng-Cashin J, McMahon E., Matshushima G, Lira SA, Cook DN, Blazar BR. T lymphocyte production of MIP-1( is critical to the recruitment of CD8+ T cells to the liver, lung and spleen during graft-versus-host disease. Blood. 96: 2973, 2000. 53. Serody, JS. Sparks, S Yin, Y., Capel E., Bigelow, S. Kirby, SL. Gabriel, D. Wiley, JM., Brecher, M., Schell, M., Folds, F. and Shea, TC. Comparison of g-CSF-mobilized peripheral blood progenitor cells and g-CSF-stimulated bone marrow as a source of stem cells in HLA-matched sibling transplantation. Biology of Blood and Marrow Transplantation. 6:434-440, 2000 54. Serody JS, Berrey MM, Albritton K, Schell M, O'Brien S, Weber DJ, Powell E, Gabriel DA, Wiley JH, Gilligan P, Shea TC. Utility of obtaining blood cultures during febrile leukopenia in bone marrow transplant recipients. Bone Marrow Transplantation. 26(5): 533-39, 2000. 55. Serody JS, Collins EJ, Tisch R, Kuhns JJ, Frelinger JA. Dendritic cell vaccination is dependent on the antigen and route and frequency of administration. Journal of Immunology 164:4961-4967, 2000 56. Cook D. N., O Smithies, RM Strieter, JA Frelinger, and JS Serody. CD8+ T cells are in vivo relevant source of MIP-1a. Journal of Immunology 162:5423-5428, 1999. 57. Serody JS, Cook DN, Kirby SL, Reap E., Shea TC, and Frelinger JA. Murine T lymphocytes incapable of producing MIP-1( are impaired in causing GVHD across a class I but not class II MHC barrier. Blood 93:43-50, 1999. 8 58. Serody JS, Brecher ME, Dent G, Bentley SA, Frelinger JA, Shea TC. A method for the production of CD4 positive CML-specific allogeneic T lymphocytes, Cancer Research 57:1547-1553, 1997. 59. Bentley SA, Brecher ME, Powell E, Serody JS, Wiley JM, Shea TC. Late engraftment failure after Marrow ablation and autologous hematopoietic reconstitution: Differences between peripheral blood stem cell and bone marrow recipients. Bone Marrow Transplantation, 19:(6), 557-563 1997. 60. Serody J, Poston RM, Weinstock D, Kurlander RJ, Frelinger JA. CD4+ cytolytic effectors are inefficient in the clearance of Listeria monocytogenes. Immunology 88:544550, 1996. 61. Bandarenko NB, Brecher ME, Owen H, Wiley J, Shea T, Serody J. Thrombocytopenia in allogeneic peripheral blood stem cell collections. Transfusion, 36:7, p 668-669, 1996. 62. Rex JH, Benrett JE, Sugar AM, Pappas PG, Serody JS, Edwards, JED, and Washburn RG. Intravascular catheter exchanges and the duration of candidemia. Clinical Infectious Disease. 21:994-6, 1995. 63. Britigan BE, Serody JS, Rosen GM and Cohen MS. Lactoferrin, as an anti inflammatory protein in professional phagocytic cells. Advances in Experimental Medicine & Biology. 357: 143-156, 1994. 64. Serody JS, Mill MR, Detterbeck FC, Harris DT and Cohen MS. Blastomycosis in transplant patents: Report of a case and review of the literature. Clinical Infectious Disease. 16(1):54-8, 1993. 65. Cohen MS, Mao J, Rasmussen GH, Serody JS and Britigan BE. Interaction of lactoferrin and lipopolysaccharide: Effects of lactoferrin antioxidant activity and priming of human neutrophils for formation of OH. Journal of Infectious Disease. 166(6):1375-9, 1992 66. Britigan BE, Serody JS, Hayek MB, Charniga LM and Cohen MS. Receptor-mediated uptake of lactoferrin by mononuclear phagocytes inhibits their ability to form hydroxyl radical. Journal of Immunology 147:4271-4277, 1991. Non Peer Reviewed Manuscripts: 1. Serody JS. Bacterial sepsis and GI tract GVHD: More commensal than you think. Blood 120(1): 6-7, 2012. 2. Serody JS, Hill GR. The IL-17 differentiation pathway and its role in transplant outcome. Biology of Blood and Marrow Transplantation. 1 Suppl) S56-61, 2012 3. Serody JS. Recertification, the good, the bad and the ugly. The Hematologist, May 2007. 9 4. Gabriel DA, Shea, T, Olajiida, O, Serody, JS, Comeau, T. The effect of oral mucositis on morbidity and mortality in bone marrow transplant. Semin Oncol 6 (Suppl 18): 76-83, 2003. 5. Shea, TS, Serody JS, Gabriel, DG, Bigelow, S, Capel E, Brecher, ME, Kirby, SL. Cytokine-stimulated bone marrow for allogeneic transplantation. Cancer Research Therapy and Control 2001. 6. Frelinger JA, and Serody JS. Immune response of beta 2-microglobulin-deficient mice to pathogens. Current Topics in Microbiology and Immunology. 232:99-114, 1998 7. Serody JS, Shea TC. Prevention of infections in bone marrow transplant recipients. Infectious Disease Clinics of North America, Vol 11, No 2, June 1997, 459-477. 8. Shea T, Graham M, Bernard S, Steagall A, Wiley J, Serody J, Brecher M, Bentley S, Johnston C, Vaisman A, Chaney S, Letrent S, Brouwer K. A clinical and pharmacokinetic study of high-dose carboplatin, paclitaxel, granulocyte colony-stimulating factor, and peripheral blood stem cells in patients with unresectable or metastatic cancer. Sem in Oncology 22:4(M), p 85-90, 1995 Book Chapters Cooke K, Coghill, J, Hildebrand G and Serody JS. Chemokines in the biology of GvHD and the GvL response. Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation. Editors Bruce Blazar and Gerald Socie, Elsevier Publishing (due December 2012). Blazar BR, Moran T, Serody JS. Th17 cells in GVHD. Th17 book, Springer Publishing New York May 2011. Peppercorn A and Serody JS. Fungal infections. Netter’s Internal Medicine Murphy, W, Serody JS and Cooke, K. Chemokine and Chemokine receptors in GVHD. Graftversus-host disease, Marcel Dekker Inc, 2004. Serody JS and Frelinger JA. Immune Response of beta 2 microglobulin-deficient mice to pathogens in Antigen Presentation. Springer Verlag, 1998. pp 99-115 Serody JS , Kelly M, and Cohen MS. Infections of immunocompromised hosts in Infectious Disease in Emergency Medicine, Lippincott, 1997. pp372-400. Serody JS and van der Horst CM. The Control of CMV Infection in Molecular Aspects of Human Cytomegalovirus Dieseases (Frontiers in Virology 2). Springer Verlag, 1993. pp 257-282 Serody JS and Cohen MS. Infections of immunocompromised hosts in Infectious Disease in Emergency Medicine, Lippincott, 1992. pp 367-385. 10 Letters 1. Serody JS, Fever in Immunocompromised Patients in the New England Journal of Medicine, 342(3): 217-18, 2000. 2. Peppercorn A, Serody JS, Cairns BA. Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA letter 300(20): 2367-2368, 2008. Abstracts: 1. Vincent B, Orellana C, Buntzman A, Scott E, Clarke S, Prins J, Serody J. Pacific Biosciences sequencing of immunoglobulin receptor repertoires. Nature Immunology/Hudson Alpha Conference, October 2012. 2. Allen JL, Wooten J, Fore M. Bhuiya NS, Armistead P. Coghill JM, Gabriel D, Roerhrs PA, Sharf A, Irons RN, Hoffert T, Richards K, Shea TC, Baldwin AB, Serody J, Sarantopoulos S. B cells from patients with chronic GVHD signal via the AKT-driven survival and metabolic fitness pathway. Biology of Blood and Marrow Transplantation. 18(2): S207S208, 2012. 3. Walko C, Ivanova A, Whitley J, Rao K, Gabriel D, Serody J, Comeau T, Coghill J, Armistead P, Sarantopoulos S, Wood W, Shea TC. Beneficial effect of high-dose IV busulfan delivered by prolonged continuous infusion on relapse rate and overall survival in matched related and unrelated allogeneic transplant patients with hematologic malignancies. Biology of Blood and Marrow Transplantation. 18(2): S218-S218, 2012. 4. Lin, KL, West ML, Jones S, Bear J, Serody JS.In vivo assessment of T effector, T regulatory cell, dendritic cell interaction in lymphoid tissue using intravital imaging during acute GVHD. Oral session, American Society of Hematology 2011. 5. Fulton, LM, Coghill JM, West ML, Foger N, Serody JS. Impaired donor T cell egress from recipient lymphoid organs profoundly leads to attenuated acute graft-versus-host disease. American Society of Hematology 2011. 6. Van Deventer HW, Hoffert T, West ML, Wu QP, Serody JS. Bone marrow stromal cells inhibit apoptosis of chronic lymphocytic leukemia cells by expressing erythroid differentiation regulatory 1. American Society of Hematology 118 (21): 769. 7. Shea TC, Waldo C, Inavova, A, Whitley J, Rao K, Gabriel DA, Comeau, T, Coghill H, Armistead P, Sarantopoulos S, Wood WA, Serody J. Beneficial effect of escalated doses of busulfan delivered by targeted pharmacokinetics and prolonged continuous infusion on relapse free and overall survival in matched related and unrelated allogeneic transplant patients with hematologic malignancies. American Society of Hematology 118(21); 845846, 2011. 8. Fitzhugh DJ, McGinnis MW, Timoshchenko R, Linninger R, Demore N, Serody J, Tarrant TK. G protein coupled receptor kinase 3 negatively regulates CXCL12/CXCR4 signaling and tumor migration in breast cancer. Journal of Allergy and Clinical Immunology 127(2): Pages AB230 2011. 9. Wood WA, Whitley J, Goyal RK, Brown P, Sharf A, Irons RN, Rao K, Essenmacher AN, Serody J, Coghill J, Armistead PM, Sarantopoulos S, Gabriel DA, Shea TC. Effectiveness and potential strategies to improve outcomes following chemomobilization with etoposide 11 plus g-CSF in patients undergoing autologous stem cell transplantation for lymphoma. American Society of Hematology. 118(21): 913-914, 2011. 10. Coghill JM, West ML, Cook DN, Serody JS. The absence of CC-chemokine receptor 8 on donor regulatory T cells impairs their ability to prevent lethal GVHD. Abstract number III522, American Society of Hematology 2010. 11. Fulton, LM, Carlson MJ, Coghill J, West ML, Panoskaltsisi-Mortari, A, Blazar BR, Littman D, Serody JS. Attentuated acute graft-versus-host disease following allogeneic stem cell transplantation in the absence of RORt. Abstract number III-521, American Society of Hematology 2010. 12. Wooten J, Nazmim BS, Richards K, Sharf A, Antin JH, Soiffer RJ, Ritz R, Shea TC, Serody J, Baldwin Jr AS, Sarantopoulos S. B cells are primed for survival by BAFF-driven BIm degradation in chronic graft-versus-host disease patients. Oral session abstract number 110A, American Society of Hematology 2010. 13. Highfill, SL, Rodriguez P, Zhou Q, Goetz CA, Veenstra R, Taylor PA, MortariPanoskaltsis, A, Serody J, Munn D, Tolar J, Ochoa AC, Blazar BR. Bone marrow myeloid-derived suppressor cells inhibit graft-versus-host disease via an arginase-1 dependant mechanism that is upregulated by IL-13 (oral session abstract 1098, American Society of Hematology 2010. 14. Voorhees PM, Gasparetto C, Richards KL, Garcia R, Strader JS, Ferraro M, MacLean J, Winans D, Moore DT, Dodd A, Foster MC, Gabrield DA, Shea TC, Serody J, Van Deventer HW, Rizvi S, Orlowski RZ, Hurd DD. Vorinostat in combination with pegylated liposomal doxorubicin and bortezomib for patients with relapsed/refractory multiple myeloma: Results of a Phase I study. American Society of Hematology 114(22): 129-130, 2009 (oral presentation). 15. Peppercorn, A, Wenink E, Serody J, Cairns B, Jones S, McKinnon K, Barnes C, Maile R, Ashton F, Schmitz J, Mach, S. A Longitudinal Study of Cytomegalovirus Reactivation and T Cell Immunity Following Burn Injury: Preliminary Analysis. Infectious Disease Society of America. September 2009, Oral session. 16. Carlson MJ, Coghill JM, West ML, Mortari AP, Blazar BR, Serody JS. CCR1 is required for Treg-mediated protection from lethal acute graft-versus-host disease. Abstract 1337, poster session. American Society of Hematology 2009 17. Voorhees PM, Gasparetto C, Richards K, Garcia R, Strader J, Ferraro M, MacLean J, Winans D, Moore DT, Dodd A, Moster M, Gabriel DA, Shea TC, Serody JS, van Deventer HW, Rizvi S, Orlowski RZ, Hurd DD. Vorinostat in combination with pegylated liposomal doxorubicin and bortezomib for patients with relapsed/refractory multiple myeloma: Results of a Phase I study. Abstract #306 oral session. American Society of Hematology 2009. 18. Tran TN, Ray GT, Saddler P, Trigg M, Hayes N, Li Y, Rizzieri DA, Stein A, Weber D, Serody J, Raasch R, Habel L. Immunocompromised status of pateints with hematologic and soldi tumor malignancies: Construction of a practical algorithm. American Society of Hematology 114(22): 980, 2009. 19. Mango RL, van Deventer HW, Wu, QP, Serody JS. Pulmonary stromal cells expressing CC chemokine receptor 5 promote metastasis via erythroid differentiation regulatory 1. Abstract 3601 poster session, American Society of Hematology 2009. 20. Foster MC, Christensen R, Egan J, Whitley J, Chiu WK, Serody J, Gabriel D, Ivanova A, Dunphy CH, Shea TC. Prognostic impact of bone marrow CD138 immunohistochemistry 12 prior to autologous stem cell transplant for multiple myeloma. American Society of Clinical Oncology, 27(15): S8600, 2009. 21. Wood WA, Deal AM, Moore DT, Whitley J, Sharf A, Serody JS, Gabriel DA, Shea TC. Usefulness of the hematopoietic cell transplantation-specific comorbidity index (HCT-CI) in predicting outcomes for adolescents and youing adults (AYAs) with hematologic malignancies undergoing allogeneic stm cell transplant. American Society of Clinical Oncology, 27(15): S7034, 2009. 22. Blazar BR, Miller JS, Panoskaltsis-Mortari A, Weigel B, Krige AM, Sharpe AH, Murphy WJ, Serody J, Hemmi H, Akira S, Levy RB, Taylor PA, In vivo effects of Toll-like receptor signaling on T-cell responses for GVHD and GVL. Journal of Pediatric Hematology Oncology, 31(4): 240-241, 2009 (oral presentation). 23. Wood WA, Walko CM, Rao KV, Whitley J, Moore DT, Gabriel DA, Serody JS, Coghill JM, Shea TC. Identificaiton of an AUC of 7603 uMol x min/hour per day x 4 days as the maximum tolerated dose of IV continuous infusion busulfan with fixed dose fludarabine in a pharmacokinetically-based dose phase I study in patients with hematologic malignancies undergoing allogeneic stem cell transplantation, American Society of Bone Marrow Transplantation, 15(2): S99, 2009. 24. Coghill, JM, Hogan KN, Serody JS. The absence of CCR7 on donor T cells leads to attenuated graft-versus-host disease (GVHD) with a preserved graft-versus-leukemia (GvL) effect. Blood, 112:810, 2008 (oral presentation). 25. Serody J, Wysocki CA, Moran TP. Recruitment of donor T cells to secondary lymphoid tissue is enhanced by conditioning therapy and donor T cells/marrow. Blood poster session 112, 3506. 26. Peppercorn A, Maile R, Barnes C, Serody J, Frelinger JA, Cairns BA. Viral reactivation and disease: A potentially important contributor to morbidity and mortality following severe burn injury. Southern Medical Journal 1900(12), S17, 2007. 27. Shea TC, Serody JS, Gabriel D, Comeau T, Ivanova A, Moore D, Irons R, Whitley J, Sharf A, Dunphy C, Brecher M. Low incidence of GVHD and treatment-related morbidity with intermediate doses of continuous infusion IV busulfan and daily fludarabine with individualized doses of alemtuzumab for matched related and unrelated transplant patients with high-risk hematologic malignancies. America Society of Hematology, 110(11): 310B, 2007. 28. Carlson MJ, Serody JS. TH17 cells mediate extensive skin pathology in acute GVHD. American Society of Hematology, #356, 2007. 29. Coghill JM, Seidel H, Serody JS. Absence of CCR4 enhances the function nof expanded regulatory T cells. American Society of Hematology #362, 2007. 30. Carlson MJ, Seidel HE, Serody JS. CD62L is not critical for T regulatory cell mediated protection from lethal acute GVHD. American Society of Hematolgoy #368, 2007. 31. Buie L, Rao KV, Epstein S, Shea TC, Comeau T, Gabriel DA, Irons R, Eron B, Serody J. Symptomatic imiprovement following intravesicular didofovir for the management of BK virus associated cystitis. American Society of Hematology, 110(11): 883A, 2007. 32. Raetzsch CF, Brooks NL, Moore KS, Marshall T, Klebanov S, Watson LJ, Trent CM, Kupper LL, Akira S, Bear JE, Serody JS, Swenberg JA, Combs TP. Chronic TLR4 and MYd88 activation causes hepatic insulin resistance by impairing PI3K inhibition of NFkappa B. American Diabetes Association Meeting, 56(Supp1): A348, 2007. 33. Shea TC, Walko C, Serody J, Gabriel D, Comeau T, Rao K, Ivanova A, Sharf A, Krasnov 13 C, Coghill J, Whitley J, Lindley C. Safety and efficacy of high-dose busulfan by 90-hour continuous infusion in hematologic malignancy patients undergoing allogeneic stem cell transplants. American Society of Bone Marrow Transplanation, 13(2): 99-100, 2007. 34. Beaven AW, Comeau TC, Sharf A, Moore DT, Serody J, Shea TC, Gabriel DA. Mitoxantrone and melphalan as conditioning regimen for autologous stem cell transplant for multiple myeloma. American Society of Hematology #174-III, 2006. 35. Taylor PA, Ehhardt MJ, Roforth MM, Swedin JM Panoslaltsis-Mortari A, Serody JS, Blazar BR. Mechanisms responsible for and strategies to overcome bone marrow rejection in allosensitized recpients. American Society of Hematology, #441-III, 2006. 36. Blazar BR, Panoskaltsis-Mortari A, Krieg AM, Kaemmi H, Akira S, Serody J, Murphy WJ, Taylor PA, In vivo CpG administration accelerates Graft-versus-host disease lethality ty Toll-like receptor 9 ligation of host antigen-presenting cells and promotes allogeneic bone marrow rejection by TLR9 ligation of donor APCs. Oral Session, American Society of Hematology, 2006. 37. Taylor PA, Ehrhardt, MJ, Panoskaltsis-Mortari, A, Serody JS, Brinkmann V, Blazar BR. FTY720 inhibits graft-versus-host disease and allogneeic bone marrow graft rejection independent of effect on T cell egress from lymphoid tissue: Oral session. American Society of Hematology 2006. 38. DuPont JA, Euliss LE, Orlowski RZ, Serody J, Hahn KM, Welch CM, Small GW, Ferer I, DeSimone JM. COLL 43-applying imprint lithography (PRINT) for the generation of hapespecific, targeted nanocarriers in medicine. American Chemical Society, 232(43-COLL), 2006. 39. Euliss LE, DuPont JA, Welch CM, Pisano E, Lin WL, Small GW, Orloski RZ, Serody J, Hahn KM, DeSimone JM. COLL-219-utilizing the emerging imprint lithography technique (PRINT) for the fabrication of shape-specific organic naonparticles for applications in nanomedicine, American Chemical Society, 232(219-COLL), 2006. 40. Lambeth C, McKinnon K, Serody J, de Dilva A. Effect of DENV3 infection of primary human dendritic cells, American Society of Tropical Medicine and Hygiene, 73(6); S240, 2005. 41. Beaven A, Shea TC, Gabriel DA, Comeau T, Irons R, Moore DT, Lin L, Sharf A, Krasnov C, Becher ME, Serody J. Long term effects on GVHD and survival following the use of GCSF stimulated bone marrow veruss G-CSF mobilized peripheral blood stem cells in HLA matched sibling transplant. American Society of Hematology S5385, 2005. 42. Shea TC, Walko C, Gabriel D, Serody J, Comeau T, Irons R, Gilman A, Krasnov C, Sharf A, Linley C. Clinical and pharmacokinetic results of a four-day continuous infusion of fulldose busulfan in patients undergoing matched related or unrelated stem cell transplant. American Society of Hematology, S1752, 2005. 43. Walko CM, Lindley CM, Collins J, Krasnov C, Harvey RD, Gabriel DA, Serody J, Comeau T, Shea TC. 90 hour continuous intravenous busulfan infusion: PK and test dose predictability in allogeneic bone marrow transplantation patients. American Society of Clinical Oncology, 23(16): 598S, 2005. 44. Harvey RD, Shea T, Walko C, Krasnow C, Patel L, Serody J, Gabriel D, Comeau T, Lindley C. Intravenous busulfan test dose clearance comparison with first and thirteenth dose systemic exposure in allogeneic bone marrow transplantation patients. American Society of Clinical Oncology, 23(16): 599S, 2005. 45. Van Deventer HW, O’Connor W, Brickey W, Ting J, Serody J. Chemokine receptor 5 14 promotes pulmonary metastasis, Federation of the American Society of Experimental Biology, 19(4): A942, 2005. 46. Shea TC, Serody J, Gabriel D, Comeau T, Morris D, Irons R, Harvey D, Sharf A, Krasnov C, Dunphy D, Bandrenko N, Brecher M. High relapse rate following alemtuzamab use in allogeneic transplants for myeloid hematologic malignancies. American Society of Bone Marrow Transplantation, 11(2): S28-29, 2005. 47. Taylor P, Panoskaltsis-Mortari A, Noelle R, Rudensky A, Serody J, Blazar B. Visualizing allogeneic bone marrow graft rejection, American Society of Hematology, Abstract 43, 2004 (oral presentation). 48. Taylor P, Panoskaltsis-Mortari A, Freeman G, Sharpe A, Noelle R, Rudensky A, Mak T, Serody J, Blazar B. The ICOS:ICOSL costimulatory pathway plays an important role in GVHD and bone marrow graft rejection. American Society of Hematology, Abstract 591, 2004. 49. O’Shaughnessy ML, Vogtenhuber C, Serody JS, Sitcheran R, Baldwin AS, Dang L, Jaffee B, Blazar BR. Ex vivo blockade of NF-kappa B signaling in alloreative T celsl prevents murine GVHD. American Society of Hematology, A3058, 2004. 50. Comeau, T, Shea, TC, Gabriel D, Morris, D, Irons, R, Harvey, D, Sharf, A, Krasnov, C, Dunphy, C, Benderenko, Brecher, M, Serody JS. BK viruria in patients undergoing allogeneic hematopoietic stem cell transplantation: Increased incidence in patients receiving alemtuzumab as conditioning therapy and lack of efficacy of cidofovir. ASH, 2004 Poster session--#3160. 51. Blazar BR, Panoskaltsis-Mortari A, Levine BB, June CH, Lucas PP, Gress R, Serody JS, Taylor PA. The role of CD4+/CD25+ T regulatory cells in allogeneic bone marrow. Blood cells, molecules and diseases, 33(3): 196, 2004. 52. Moran, TP, Collier M, Davis NL, McKinnon KP, Serody JS, Johnston RE. Transduction of human and murine dendritic cells with Venezuelan equine encephalitis virus replicon particles: A potential method for inducing tumor immunity. American Society of Virology Poster Session #9, Abstract 14, 2004 53. Van Deventer HW, Ng-Cashin J, Kuhns, JJ, Ting YPJ, Serody, JS. Differences in the Growth of Local vs Metastatic Melanoma After T Regulatory Cell Depletion. American Association of Immunology, 2004 54. Wysocki, C, Burkett, S, Chwastiak, K, Taylor, P, Blazar, BR, Serody JS. CCR5 Expression on CD4+CD25+ Regulatory T Cells Plays a Critical Role in Their Ability To Prevent GVHD. American Society of Hematology, 517, 2003 (oral presentation). 55. Mortari, AP, Price, AP, Hermanson, JR, Taras, E, Lees, C, Serody JS, Blazar, BR. In Vivo Imaging of Graft-versus-Host-Disease (GVHD) in Mice. American Society of Hematology,513, 2003 (oral presentation). 56. Comeau, T, Serody J, Gabriel DA, Wiley, J, Kirby, S, Iron, R, Hill, D, Tuttle, R, Wilson, C, Kok, B, Bandarenko, N, Brecher, ME, Shea, TC. Combined Infusion of Peripheral Blood Stem Cells (PBSC) Bone Marrow (BM) in Poorly Mobilizing Patients Undergoing High-Dose Therapy (HDT) and Autologous Stem Cell Transplant (ASCT). American Society of Hematology, 988A, 2003. 57. O’Shaughnessy MJ, Vogtenhuber C, Serody J, Sitcheran R, Baldwin A, Dang L, Adams J. Blazar BR. Ex vivo blockade of NF-kappa B signaling in alloreactive T cells prevents murine GVHD. Federation of the American Society of Experimental Biology, 17(7): C60, 2003. 15 58. Moran, T, Long, B, Collier M, Davis, NL, McKinnon, KP, Ng-Cashin J, Johnston, R, Tisch, R, and Serody JS. In vivo and in vitro activities of Venezuelan equine encephalitis viral replicons encoding HER-2/neu in the prevention and treatment of breast cancer. 11th SPORE Meeting, Baltimore MD, #116, 2003. 59. O’Shaughnessy, MJ, Vogtenhuber C, Serody JS, Sitcheran, R, Baldwin A, Dang, L, Adams, J, Blazar, BR. Ex vivo Blockade of NF-(B Signaling in Alloreactive T cells Prevents Murine Graft-versus-host Disease (GVHD). American Association of Immunology. Transplantation Immunology 1, 37.9, Denver CO. 2003. 60. Bushman JE, Mauriello CT, Walton WG, McKinnon KP, Serody JS, Kirby SL. Effects of a truncated erythropoietin receptor (tEpoR) transgene on proliferation and function of dendritic cells derived from murine bone marrow. American Society of Hematology, 100(11): 404A, 2002. 61. Wysocki CA, Burkett SB, Kirby SL, McKinnon K, Craven R, Blazar BR, Serody JS. Absence of CCR5 on donor T cell accelerates GVHD. American Society of Hematology, A5200, 2002. 62. Gabriel DA, Shea T, Serody J, Kirby S, Bigelow S, Kanamond L, Moore DT, Irons R. Cytoprotection by amifostine during autologous stem cell transplant for advanced refractory hematologic malignancies. American Society of Hematology, 415A, 2002. 63. Engelhardt B, Serody J, Gabriel D, Kirby S, Wily J, Bigelow S, Harvey D, Moore D, Gilligan P, Banderenko N, Shea T. Use of prophylactic ganciclovir and CMV antigen screening in allogeneic transplant patients receiving high-dose steroids. American Society of Hematology, A5342, 2002. 64. Shea T, Gabriel D, Kirby S, Serody J, Tsuie A, Capel E, Bigelow S, Booker J, Brecher M, Banderenko N, Wiley J. Non-myeloablative transplants using cyclophosphamide and fludarabine with g-CSF stimulated bone marrow. American Society of Hematology, A5304, 2001. 65. Panoskaltsis-Mortari A, Hermanson JR, Serody JS, Blazar BR. Acceleration of idiopathic pneumonia syndrome in the absence of door macrophage inflammatory protein-1 alpha following allogeneic bone marrow transplant in mice. Federtion of the American Society of Experimental Biology, 15(4): A359, 2001. 66. Dees EC, McKinon K, Myers M, Sparks SD, Chwastiak K, Collichio F, vanDeventer HW, Carey LA, Brecher ME, Graham M, Serody JS. Phase I clinical trial of HER2 peptidepulsed autologous dendritic cells in patients with metastatic breast cancer, Breast Cancer Research and Treatment, 59(3): 311, 2001. 67. Gabriel DA, Serody JS, Kirby S, Capel E, Bigelow S, Moore D, Shea TC. Efficacy of peripheral blood stem cell or mobilized marrow transplant in the treatment of refractory multiple myeloma. American Society of Hematology, A5283, 2000. 68. Shea TC, Wiley J, Serody J, Gabriel D, Powell E, Bigelow S, Schultz S, Brecher M, Bentley S, Lin Y, Schell M. Fixed dose G-CSF post autologous peripheral blood stem cell transplantation permits utilization of lower doses of growth factor without compromising engraftment. American Society of Hematology, A525, 1998 (oral presentation). 69. Gabriel DA, Melton LG, Thompson CM, Shea TC, Serody JS, Wiley JM, Powell E, Bigelow S. Transient impact of stem cell infusion on platelet function. American Society of Hematology, A4388, 1998. 70. Serody JS, Cook D, Reap E, Cohen P, Freligner JA, Shea TC. Blockade of T lymphocyte production of the chemokine MIP-1 alpha decreases the severity and time to onset of 16 chronic GVHD across a clas I but not class II MHC barrier. American Society of Hematology 90(10): 909, 1997. 71. Shea T, Wiley J, Serody J, Gabriel D, Powell E, Scott C, Banderenko N, Brecher M, Bentley S. CD-34 mobilization with intermediate dose cyclophosphamide, paclitaxel and G-CSF. American Society of Hematology, 90(1): 4260, 1997. 72. Wiley, J, Shea T, Powell E, Serody J, Gabriel D, Sailer S, Killian D, Bentley S, Brecher M. A phase I-II study of cyclophosphamide, VP-16, carboplatin and total body irradiation with autologous stem cell transplantation for acute leukemia. American Society of Hematology, 88(1): 3702, 1997. 73. Serody J, Brecher M, Shea T, Frelinger J. Production of allogeneic leukemia-specific CD4+ lymphocytes in vitro. American Society of Hematology, 86(10): 617, 1995. 74. Gray F, Shea T, Wiley J, Serody J, Powell E, LaChapelle J, Pope B, Sailer S, Bentley S, Brecher M. Phase I/II results of cyclophosphamide, VP-16, carboplatin and total body irradiation with autologous stem cell transplantation for hematologic malignancies. American Society of Hematology, 86(10): 3778, 1995. 75. Serody J, Wiley JM, Gabriel DA, Powell E, Scott C, Lawrence P, Bentley SA, Brecher ME, Folds F and Shea TC. Comparison of the use of G-CSF stimulated peripheral blood stem cells or G-CSF-stimulated Bone Marrow in six antigen matched allogeneic transplantation. Proceedings of ASCO, 1997. 76. Serody JS, Berry MM, Weber DJ, Schell MJ, O'Brien SM, Gabriel DA, Wiley JM, Gilligan PH and Shea TC. Utility of blood cultures during febrile leukopenia in bone marrow transplant recipients. Proceedings of ASCO, 16:413a, number 1474, 1997. 77. Berrey MM, Weber DJ, Schell M, Powell E, Gilligan P, Gabriel DA, Wiley JM, Shea TC, Serody JS. Utility of blood cultures in bone marrow transplant recipients with leukopenia. Proceedings of ASCO oral presentation 1995. 78. Shea T, Wiley J, Serody J, Mason J, Powell E, Van Le L and Fowler W. High-dose chemotherapy with melphalan, VP-16, carboplatin, thiotepa, and mitoxantrone in patients with advanced epithelial ovarian cancer. Proc ASCO 14:462, 1995. (Abstract 1492). 79. Shea T, Graham M, Bernard S, Steagall, Wiley J, Serody J, Johnston C, Brecher M, Bentley S, Van Le L and Fowler W. Multiple cycles of high dose paclitaxel plus excalating doses of carboplatin with G-CSF (filgrastim) and peripheral blood stem cell (PBSC) support. Proc ASCO 14:478, 1995. (Abstract 1555). 80. Shea T, Wiley J, Sailer S, Powell P, Serody J, Mason J, Storniolo AM, Seagren S, Bentley S and Brecher M. A phase I study of cyclophosphamide, VP-16, carboplatin, and total body irradiation with autologous stem cell transplantation for hematologic tumors. J. of Cellular Biochemistry. Abstract Supplement 18B(83), 1994 81. Serody JS, Charniga LM and Cohen MS. Identification of a putative lacoferrin receptor on the monocytoid cell line U937. Clinical Research 39:1990. 82. Serody JS, Weber RD, Hassett DJ, Charniga LM, Yount PL and Cohen MS. Physiologic response of U937 cells to redox stress: Demonstration of novel heat shock proteins. Clinical Research 38:394A, 1990. Invited Abstracts: Blazar, BR, Panoskaltsis-Mortari, Serody JS, Lees, CJ, Erhhardt MJ, Swedin JM, Murphy WJ, Noelle RJ, Levine BL, June CH, Sagaguchi S, Taylor P. The role of CD4+CD25+ T regulatory 17 (Treg) cells in allogeneic bone marrow transplantation. (BMT). Keystone Symposia on regulatory T cells, Banff Alberta, 2003. Dees EC, McKinnon K, Myers M, Sparks S, Chwastiak K, Collichio F, vanDeventer H, Carey L, Brecher ME, Graham M, Serody JS. Phase I clinical trial of HER2 peptide-pulsed autologous dendritic cells in patients with metastatic breast cancer (MBC). Oral Presentation at the 9th Annual SPORE Meeting, 2001. Licensure: Board Certified Hematology 1996/recertified 2007 Board Certified Internal Medicine 1989 Medical license North Carolina 1987 Membership Professional Societies: American Society for the Advancement of Science American Society of Bone Marrow Transplantation American Society of Clinical Oncology American Society of Hematology American Association of Immunology Infectious Disease Society of America International Society for the Biological Therapy of Cancer Southern Bone Marrow Transplant Society Professional Service (Consultant): Pharmacia Incorporated on a project evaluating the use of glutamine to enhance TPN in bone marrow transplant patients CellPro, Incorporated on a protocol to evaluate the use of the CD34+ selection system in patients with lymphoma Merck, Sharpe & Dohme - Monotherapy for neutropenia Data Safety Monitoring Board for Glaxo Wellcome evaluation hematological toxicity of antidepressant Management of fever and neutropenia Elan Pharmaceuticals Evaluation of Patient Populations to administer Oka/Merck Varicella Zoster Vaccine—Merck Data Safety Monitoring Board for Immtech Pharmaceutical anti-infective studies 18 Consultant for pharmacological therapy for inflammatory diseases TheraLogics Consultant for Approaches to Diminish Acute/Chronic GvHD: Novartis Editorial Positions: Editorial Board: Journal of Clinical Oncology 2009-2012 Editorial Board: Blood 2011-present Associate Guest Editor: Blood 2012 Abstract Section Head Reviewer Infectious Disease Society of America Immunocompromised Host Section 1996 Abstract Reviewer Tumor Immunotherapy ASH 2008 Ad-Hoc Journal Reviewer: American Journal of Hematology American Journal of Transplantation Biology of Blood and Marrow Transplantation Blood Bone Marrow Transplantation Cancer Research Clinical and Laboratory Haematology Clinical Cancer Research Journal of Clinical Investigation Journal of Clinical Oncology Journal of Hepatology Journal of Immunology Journal of Immunotherapy Journal of Virology Leukemia and Lymphoma Melanoma Research Nature Medicine Proceedings of the National Academy of Sciences USA Science Translational Medicine Stem Cells Vaccine Previous Grants Funded: UCRF Grant: Multimodality Therapy for Breast Cancer: 2009-2011 STTR Phase 1 and Phase 2 Grants: Blockade of NF-B for the Prevention/Treatment GvHD 2007-2011 R01: Treg Migration in GvHD: 2004-2009 R01: Mechanisms of T cell Trafficking in GVHD 2003-2008 ARRA Supplement to Treg Migration in GVHD Grant: 2010 R56: Treg Migration in GVHD: 2011 R21: Combined Modality Therapy for the Treatment of Patients with Metastatic Breast Cancer who Express HLA-A0201 19 Lineberger Clinical Cancer Center Small Grant Award 2003-04 R21: Immunotherapy for the Treatment of Metastatic Breast Cancer 2000-02 KO8 Award National Cancer Institute 1996-2001 Lineberger Clinical Cancer Center Small Grant Award, 1995-96 National Research Service Award 1991-1992 Teaching Experience: 2011 Co-course Director Microbiology 212 Seminar on T cell fate determination 2010-current Lecture on Why Immunology is Important for Clinical Medicine to first year medical students 2008-current Lecture on Hodgkin’s Lymphoma to Hematology/Oncology Fellows 2006-2011 Lecture on Transplantation Immunology to first year medical students 2005-current Lecture to Hematology/Oncology Fellows concerning tumor immunology 2000-current Lecturer for Hematology/Oncology Fellows Infections in Cancer Patients 1999-2011 Lecture on Tumor Immunology in First Year Medical School Immunology Class 2003 Course Director Microbiology 212 Seminar in Innate Immunity 2000-2002 Lecturer for Hematology/Oncology Fellows Tumor Immunology 1999 Course Director Microbiology 212 Seminar in Dendritic Cell Biology 1996-2004 Lecturer Bimonthly Fever and Neutropenia Treatment to the Housestaff and Students 1994--1997 Lecturer Nutrition 221: Tumor Immunology 1996 - 2004 Lecturer Cancer Pathology 213 Tumor Immunology for Graduate Students 1996 1998 Medical School Lecture T cell Activation and GVHD 1995 – 1996 Laboratory Instructor, Hematology 1995 - 2002 Laboratory Instructor for Microbiology and Immunology 1993 - 1994 Clinical Pathology Conference UNC Chapel Hill Grand Rounds and Continuing Medical Education Lectures 2012: Transplantation Immunology Grand Rounds: “Intravital Imaging and Regulatory T cell Function”, Medical College of Wisconsin, Milwaukee, WI 2012: Transplantation Immunology Grand Rounds MD Anderson Cancer Center: “Mechanisms of action of regulatory T cells using intravital imaging.” 2012: Management of Patients with Hodgkin’s Lymphoma: Medical Grand Rounds, New Hanover Medical Center, Wilmington NC 2012: Th17 Cells and GVHD Symposium at American Society for Bone Marrow Transplantation Meeting San Diego CA: “Th17/Th22 Cells in Acute GvHD; Lead Actors or Bit Players.” 2012 Oncology Grand Rounds Wake Forest Baptist Hospital: T cell subsets and GVHD 2011 American Association of Immunology Meeting Presidential Symposium: Stem Cell Transplantation from the miraculous to the mundane 2010 UAB Departmental Grand Rounds: Targeting lymphoid migration to Prevent GvHD: 2009: Transplant Immunology Seminar Series MD Anderson Cancer Center: Chemkines and GVHD 2009 Immunology Department Seminar Series: Duke University School of Medicine 2009 Oncology Seminar Series: East Carolina School of Medicine 2009 Pathology Grand Rounds UNC School of Medicine 20 2008 UAB Cancer Center: Migration is Critical for the Good and the Bad 2008 Cancer Center Grand Rounds City of Hope Medical Center T cell Subsets Migration and GVHD 2005 Grand Rounds Medical University of South Carolina:--Migration Important in GVHD and Tumor Vaccination 2005: Oncology Grand Rounds Lineberger Comprehensive Cancer Center: Migration and GVHD and Tumor Vaccination 2004 Duke Hematology/Oncology Symposia Treatment of Fungal Infections in Transplant Patients 2003 Medical School Research Symposium 2003 Vaccine Therapy for Breast Cancer: From Bench to Patients and Back 2003 Grand Rounds New Hanover Medical Center Tumor Immunology 2003 BMT Grand Rounds DUMC Fungal Infections in BMT Patients 2001 BMT Grand Rounds Duke University Hospital Infection in BMT Patients 2001 BMT Grand Rounds University of Minnesota Chemokines in Transplantation 2001 Grand Rounds at CMC Charlotte NC Update on New Antifungal Drugs 1999 Grand Rounds at CMC Charlotte NC; Management of Febrile Cancer Patients 1998 BMT Grand Rounds University of Colorado Chemokines and GVHD 1998 Grand Rounds: University of Tennessee at Knoxville. Update on Fever and Neutropenia 1998 AHEC:Lecture on Fever and Neutropenia. Carolinas Medical Center 1998 AHEC:Lecture on Fever and Neutropenia. Rex Medical Center 1995 AHEC:Lecture on bone marrow transplantation for CML Wake Medical Center Postdoctoral Fellows Trained in Serody Laboratory *Hank Van Deventer MD Jennifer Kuhns PhD Judith Ng-Cashin MD John Powderly MD Heather Shearer MD James Coghill MD Michael Carlson PhD Laura Ott PhD Current Postdoctoral Fellows in the Laboratory: Kaifeng Lin PhD Benjamin Vincent MD Grace Kim MD Malini Boomiasami PhD Graduate Student Laboratory Work: Supervisor for Julia Gambone Immunology Rotation 2010 Supervisor for Meghan Free Immunology Rotation 2009 Supervisor for Ginny Hench Immunology Rotation 2003 Supervisor for Kristopher Curtis Immunology Rotation 1999 Supervisor for Karen Albritton MD clinical research rotation 1997 21 Supervisor for M Michelle Berrey MD on a clinical research rotation September 1995 Basic Science Teaching Supervisor for LeShara Fulton 2009 IBMS Program Supervisor for Nick Taylor 2010 MD PhD Program Supervisor for Trisha Dant 2012 *co-trained with Jenny Ting PhD Students Completed Training: Timothy Moran MD PhD Program; PhD Completed 2006 Christian Wysocki MD PhD Program: PhD Completed 2005 Joseph Burgents PhD IBMS Program: PhD Completed 2010 Robert Mango PhD in the MD PhD program Completed 2010 Laura Greene 2005-2006: Left to attend Veterinary School. Current Graduate Students: Nick Taylor (MD PhD Program) LeShara Fulton (HHMI Translational Medicine Program) Trisha Dant Committee Memberships Graduate School: Eileen McMahon Jeffrey MacKeigan Brian Long Shannon Pop Cassandra Lambeth Reed Shabman Kelly Roney Meredith Burgents (DDS Program) Ginnie Hench Sarah Stein Eda Holl Alaina Garland Mark Johnson Reid Roberts (Chair) Amy Beres (External Reader Medical College of Wisconsin PhD program) Microbiology/Immunology Preliminary Committees: Reid Roberts Mark Johnson Eric Meissner Jin Hyang Kim Undergraduate Students Rotating Through Laboratory: Janelle Vargas 22 Ivana Ferrer Robin Craven Richard Park Bureaucratic Duties: -Director of Oncology Grand Rounds Lineberger Comprehensive Cancer Center -Member Educational Committee for the Hematology Oncology Fellowship Program -Member of the Executive Committee for the Division of Hematology and Oncology University of North Carolina at Chapel Hill -Member of the Program Planning Committee Lineberger Comprehensive Cancer Center - GRANT INFORMATION Active National Institutes of Health (Serody) 7/1/2012-6/30/2017 Direct $250,000 Targeting CCR7 for the Treatment/Prevention of GvHD RO1 CA163725 The goals of this work are to evaluate approaches to block T cell migration to prevent/treat GVHD National Institutes of Health (Serody) 4/1/2012-3/30/2017 Direct $186,500 Th1/Th17 cell macrophages interactions in cutaneous GvHD RO1CA166794 The goals of this work are to investigate the function of Th17 and Th22 cells in acute and chronic GvHD Leukemia and Lymphoma Society (Serody) 10/1/2010-9/30/2013 Direct $178,200 Blocking T cell Effector Function in GVHD The goals of this work are to evaluate translational approaches to block organ-specific GVHD by targeting T cells responsible for tissue injury Susan G.Komen For the Cure (Serody) 7/1/2010-6/30/2013 Direct $150,000 KG100307 Combined Modality Therapies for the Treatment of Metastatic Breast Cancer 10% effort The goals of this work are to combine dendritic cell vaccination with vinorelbine and trastuzumab for the treatment of patients with metastatic breast cancer National Institutes of Health (Earp) 9/1/2012-8/31/2017 SPORE in Breast Cancer $220,000 Project 2 Function of the immune infiltrating cells in the biology of claudin-low and basal-like breast 23 cancer The goals of this project are to evaluate the activity of immune cells in basal-like and claudinlow breast cancer Breast Cancer Research Foundation (Earp) 7/01/09-6/30/10 Direct $28,000 Immunotherapy for Breast Cancer This grant supports a clinical trial involving the use of vaccine therapy with chemotherapy and a biological response modifier National Institutes of Health (Earp) 6/1/2004-11/30/2010 Cancer Center Core Support Grant P30CA016086 This supports Dr. Serody’s role as co-leader of the Immunology program of the Lineberger Cancer Center and as leader of the malignant hematology program National Institutes of Health (Key) 4/1/2007-3/30/2012 Research Fellowships in Hematology Oncology T32HL007149 5% effort (no salary requested) Dr. Serody directs the malignant hematology research fellowship section for this T32 proposal. Glaxo Smith Klein (Serody) 7/1/2011-6/30/2013 Direct $152,000 Immune Assessment Post Vaccination The goals of this work are to evaluate T cell activity after infectious disease vaccination. National Institutes of Health (Coghill) 4-1-2012-3-31-2017 K08HL11205 Dr. Serody serves as one of the two co-mentors for Dr. Coghill National Institutes of Health (Sarantopoulos) 7-12-2011-6-30-2015 K08HL107756 Dr. Serody serves as one of the two co-mentors for Dr. Sarantopoulos Leukemia and Lymphoma Society (Lin) Dr. Serody serves as the mentor for Dr. Lin’s fellowship grant. 7-1-2012-6-30-2015 Committee Memberships: 2012-current 2012-current 2009-current 2009-current 2007-current 2003-current 2005-2010 LCCC T32 Fellowship Selection Committee Core Facilities Advocacy Committee: Clinical Cores Protocol Office Executive Committee LCCC Animal Space Use Committee School of Medicine UNC-CH University Cancer Fund Equipment Committee Flow Cytometry Committee UNC Chair Lineberger Cancer Center Translational Research Grant Committee 24 2005-2008 2005-current 2005-current 2004-2007 1995-1998 1996-current 1996-2006 School of Medicine Research Advisory Committee Division of Hematology and Oncology Educational Committee Division of Hematology and Oncology Executive Committee Member of the University of North Carolina Data Safety Monitoring Board Lineberger Comprehensive Cancer Center Advisory Committee Antibiotics and Therapeutics Subcommittee, UNC-Chapel Hill Pharmacy and Therapeutics Committee, UNC-Chapel Hill Attending Duties: Clinical Service six weeks each year on the Clinical Bone Marrow Transplantation Service and malignant hematology inpatient service Patents and IND’s IND number BB#8037 from the FDA for the use of peptide based vaccine therapy for the treatment of patients with metastatic breast and locally advanced ovarian cancer 25